Clinics in Chest Medicine (CLIN CHEST MED)

Publisher: WB Saunders

Journal description

Each issue of Clinics in Chest Medicine reviews new diagnostic and management techniques for a single clinical problem--and makes them simple to apply. Its concise, comprehensive, and its editors and authors are respected experts.

Current impact factor: 2.07

Impact Factor Rankings

2015 Impact Factor Available summer 2016
2014 Impact Factor 2.074
2013 Impact Factor 2.168
2012 Impact Factor 2.066
2011 Impact Factor 3.284
2010 Impact Factor 3.11
2009 Impact Factor 2.505
2008 Impact Factor 2.357
2007 Impact Factor 1.858
2006 Impact Factor 1.991
2005 Impact Factor 1.456
2004 Impact Factor 1.65
2003 Impact Factor 1.308
2002 Impact Factor 2.026
2001 Impact Factor 1.891
2000 Impact Factor 1.627
1999 Impact Factor 2.042
1998 Impact Factor 1.316
1997 Impact Factor 1.307
1996 Impact Factor 1.133
1995 Impact Factor 1.105
1994 Impact Factor 1.027
1993 Impact Factor 0.972
1992 Impact Factor 1.785

Impact factor over time

Impact factor

Additional details

5-year impact 2.24
Cited half-life 8.10
Immediacy index 0.65
Eigenfactor 0.00
Article influence 0.75
Website Clinics in Chest Medicine website
Other titles Clinics in chest medicine
ISSN 0272-5231
OCLC 5433901
Material type Periodical, Internet resource
Document type Journal / Magazine / Newspaper, Internet Resource

Publisher details

WB Saunders

  • Pre-print
    • Author can archive a pre-print version
  • Post-print
    • Author can archive a post-print version
  • Conditions
    • Pre-print allowed on any website or open access repository
    • Voluntary deposit by author of authors post-print allowed on institutions open scholarly website including Institutional Repository, without embargo, where there is not a policy or mandate
    • Deposit due to Funding Body, Institutional and Governmental policy or mandate only allowed where separate agreement between repository and the publisher exists.
    • Permitted deposit due to Funding Body, Institutional and Governmental policy or mandate, may be required to comply with embargo periods of 12 months to 48 months
    • Set statement to accompany deposit
    • Published source must be acknowledged
    • Must link to journal home page or articles' DOI
    • Publisher's version/PDF cannot be used
    • Articles in some journals can be made Open Access on payment of additional charge
    • NIH Authors articles will be submitted to PubMed Central after 12 months
    • Authors who are required to deposit in subject-based repositories may also use Sponsorship Option
    • Publisher last reviewed on 03/07/2015
    • 'WB Saunders' is an imprint of 'Elsevier'
  • Classification
    ​ green

Publications in this journal

  • Clinics in Chest Medicine 06/2015; 36(2). DOI:10.1016/S0272-5231(15)00039-8
  • [Show abstract] [Hide abstract]
    ABSTRACT: Primary lung cancer is the leading cause of cancer mortality in the world. Thorough clinical staging of patients with lung cancer is important, because therapeutic options and management are to a considerable degree dependent on stage at presentation. Radiologic imaging is an essential component of clinical staging, including chest radiography in some cases, computed tomography, MRI, and PET. Multiplanar imaging modalities allow assessment of features that are important for surgical, oncologic, and radiation therapy planning, including size of the primary tumor, location and relationship to normal anatomic structures in the thorax, and existence of nodal and/or metastatic disease. Copyright © 2015 Elsevier Inc. All rights reserved.
    Clinics in Chest Medicine 04/2015; 36(2). DOI:10.1016/j.ccm.2015.02.004
  • [Show abstract] [Hide abstract]
    ABSTRACT: Low-dose computed tomographic (LDCT) screening is now moving from clinical trials to clinical practice, following the report from the National Lung Screening Trial that LDCT screening for lung cancer can reduce the number of deaths from lung cancer by 20% in current and former smokers, ages 55 to 74 years, with a 30 pack-year smoking history. This article reviews the current evidence for screening, key elements of a successful lung cancer screening clinic, and reporting and management guidelines for LDCT screening findings. Copyright © 2015 Elsevier Inc. All rights reserved.
    Clinics in Chest Medicine 04/2015; 36(2). DOI:10.1016/j.ccm.2015.02.002
  • [Show abstract] [Hide abstract]
    ABSTRACT: The development of widespread lung cancer screening programs has the potential to dramatically increase the number of thoracic computed tomography (CT) examinations performed annually in the United States, resulting in a greater number of newly detected, indeterminate solitary pulmonary nodules (SPNs). Additional imaging studies, such as fluorodeoxyglucose F 18 (FDG)-positron emission tomography (PET), have been shown to provide valuable information in the assessment of indeterminate SPNs. Newer technologies, such as contrast-enhanced dual-energy chest CT and FDG-PET/CT, also have the potential to facilitate diagnosis of potentially malignant SPNs. Copyright © 2015 Elsevier Inc. All rights reserved.
    Clinics in Chest Medicine 04/2015; 36(2). DOI:10.1016/j.ccm.2015.02.003
  • [Show abstract] [Hide abstract]
    ABSTRACT: Pulmonary involvement is a frequent manifestation of connective tissue disease (CTD)-related thoracic disease. It is important to characterize the underlying pattern when pulmonary involvement occurs in a patient with CTD, and to exclude other causes. A systematic approach, evaluating each compartment of the lung (airway, interstitium, pleura, pulmonary vasculature) may be helpful. In complex cases, a multidisciplinary approach should be considered, potentially including the pulmonologist, rheumatologist, radiologist, pathologist, and sometimes the infectious disease specialist or oncologist. New techniques, such as quantitative computed tomography and MRI, are expected to be helpful for evaluation and management of CTD-associated thoracic disease. Copyright © 2015 Elsevier Inc. All rights reserved.
    Clinics in Chest Medicine 04/2015; 36(2). DOI:10.1016/j.ccm.2015.02.010
  • [Show abstract] [Hide abstract]
    ABSTRACT: Chest radiography serves a crucial role in imaging of the critically ill. It is essential in ensuring the proper positioning of support and monitoring equipment, and in evaluating for potential complications of this equipment. The radiograph is useful in diagnosing and evaluating the progression of atelectasis, aspiration, pulmonary edema, pneumonia, and pleural fluid collections. Computed tomography can be useful when the clinical and radiologic presentations are discrepant, the patient is not responding to therapy, or in further defining the pattern and distribution of a radiographic abnormality. Copyright © 2015 Elsevier Inc. All rights reserved.
    Clinics in Chest Medicine 04/2015; 36(2). DOI:10.1016/j.ccm.2015.02.006
  • [Show abstract] [Hide abstract]
    ABSTRACT: The idiopathic interstitial pneumonias are a group of inflammatory and fibrosing pulmonary conditions that share many clinical, radiologic, and histologic similarities. Radiologic evaluation can often help to make a more confident diagnosis of these conditions and may help in their management. Several specific radiologic findings can suggest a single best diagnosis or can help to differentiate between similar conditions. Imaging findings can also have important prognostic implications or identify complications. This review discusses the role of radiologic findings in the setting of the idiopathic interstitial pneumonias. Copyright © 2015 Elsevier Inc. All rights reserved.
    Clinics in Chest Medicine 04/2015; 36(2). DOI:10.1016/j.ccm.2015.02.009
  • [Show abstract] [Hide abstract]
    ABSTRACT: Pulmonary vascular diseases encompass a large and diverse group of underlying pathologies ranging from venous thromboembolism to congenital malformations to inflammatory vasculitides. As a result, patients can present either acutely with dyspnea and chest pain or chronically with dyspnea on exertion, hypoxia, and right heart failure. Imaging, particularly with multidetector CT, plays a key role in the evaluation and management of patients with suspected pulmonary vascular disease and, given the widespread routine use of high-quality CT pulmonary angiography, it is imperative that radiologists be familiar these pathologies. Copyright © 2015 Elsevier Inc. All rights reserved.
    Clinics in Chest Medicine 03/2015; 36(2). DOI:10.1016/j.ccm.2015.02.007
  • [Show abstract] [Hide abstract]
    ABSTRACT: Diseases and therapies that reduce cell-mediated immunity increase the risk of nontuberculous mycobacterial (NTM) disease. Extrapulmonary NTM disease, including disseminated, skin, and catheter-related disease, is more common in immunosuppressed than immunocompetent patients. Mycobacterium avium complex remains the most common cause of NTM infection, but rapid growers including Mycobacterium abscessus, Mycobacterium chelonae, and Mycobacterium fortuitum play an important role in skin and catheter-related infections. With the exception of antibiotic prophylaxis for AIDS patients, the prevention of NTM remains difficult. Management is complicated, involving restoration of immune function and removal of catheters in addition to treatment with species-specific antibiotics per current guidelines. Copyright © 2015 Elsevier Inc. All rights reserved.
    Clinics in Chest Medicine 03/2015; 36(1):91-99. DOI:10.1016/j.ccm.2014.11.002
  • Clinics in Chest Medicine 03/2015; 36(1):XIII-XIII.
  • [Show abstract] [Hide abstract]
    ABSTRACT: Rapidly growing mycobacteria (RGM) include a diverse group of species. We address the treatment of the most commonly isolated RGM-M abscessus complex, M fortuitum, and M chelonae. The M abscessus complex is composed of 3 closely related species: M abscessus senso stricto (hereafter M abscessus), M massiliense, and M bolletii. Most studies address treatment of M abscessus complex, which accounts for 80% of lung disease caused by RGM and is the second most common RGM to cause extrapulmonary disease (after M fortuitum). The M abscessus complex represent the most drug-resistant nontuberculous mycobacteria and are the most difficult to treat. Copyright © 2015 Elsevier Inc. All rights reserved.
    Clinics in Chest Medicine 03/2015; 36(1):67-78. DOI:10.1016/j.ccm.2014.10.004
  • [Show abstract] [Hide abstract]
    ABSTRACT: The incidence of pulmonary nontuberculous mycobacterial disease is increasing. Despite aggressive medical therapy, a subset of patients will experience treatment failure or suffer disabling or life-threatening symptoms. The use of anatomic lung resection in addition to optimal medical management may, in select cases, result in improved clinical outcomes. More data are needed to confirm this approach. For those with nontuberculous mycobacterial infection, treatment in a multidisciplinary setting including surgeons familiar with operative techniques specific to infectious lung disease will improve patient care. Copyright © 2015 Elsevier Inc. All rights reserved.
    Clinics in Chest Medicine 03/2015; 36(1):117-122. DOI:10.1016/j.ccm.2014.11.004
  • [Show abstract] [Hide abstract]
    ABSTRACT: Nontuberculous mycobacteria (NTM) are important emerging cystic fibrosis (CF) pathogens. Factors including the steady aging of the CF population, the apparent increase of NTM in the environment, and the potential for patient-to-patient transmission, may contribute to increased acquisition. Diagnosis of NTM disease is challenging due to disease overlap; thus, comprehensive care of the CF patient must be optimized to assess the clinical impact of the NTM (indolent versus active), and to improve response to treatment. The development of a CF-specific approach to the diagnosis and treatment of NTM infection is a research priority for the CF community. Copyright © 2015 Elsevier Inc. All rights reserved.
    Clinics in Chest Medicine 03/2015; 36(1):101-115. DOI:10.1016/j.ccm.2014.11.003
  • [Show abstract] [Hide abstract]
    ABSTRACT: This article discusses obesity, its contribution to clinical outcomes, and the current literature on nutrition. More than one third of Americans are obese. Literature suggests that, among critically ill patients, the relationship between obesity and outcomes is complex. Obese patients may be at greater risk of developing acute respiratory distress syndrome (ARDS) than normal weight patients. Although obesity may confer greater morbidity in intensive care, it seems to decrease mortality. ARDS is a catabolic state; patients demonstrate a profound inflammatory response, multiple organ dysfunction, and hypermetabolism, often with malnutrition. The concept of pharmaconutrition has emerged. Copyright © 2014 Elsevier Inc. All rights reserved.
    Clinics in Chest Medicine 12/2014; 35(4). DOI:10.1016/j.ccm.2014.08.005
  • [Show abstract] [Hide abstract]
    ABSTRACT: Given the high incidence and mortality of acute respiratory distress syndrome (ARDS) in critically ill patients, every practitioner needs a bedside approach both for early identification of patients at risk for ARDS and for the appropriate evaluation of patients who meet the diagnostic criteria of ARDS. Recent advances such as the Lung Injury Prediction score, the Early Acute Lung Injury score, and validation of the SpO2/Fio2 ratio for assessing the degree of hypoxemia are all practical tools to aid the practitioner in caring for patients at risk of ARDS. Copyright © 2014 Elsevier Inc. All rights reserved.
    Clinics in Chest Medicine 12/2014; 35(4). DOI:10.1016/j.ccm.2014.08.007
  • [Show abstract] [Hide abstract]
    ABSTRACT: Regenerative medicine has entered a rapid phase of discovery, and much has been learned in recent years about the lung's response to injury. This article first summarizes the cellular and molecular mechanisms that damage the alveolar-capillary barrier, producing acute respiratory distress syndrome (ARDS). The latest understanding of endogenous repair processes is discussed, highlighting the diversity of lung epithelial progenitor cell populations and their regulation in health and disease. Finally, the past, present, and future of exogenous cell-based therapies for ARDS is reviewed. Copyright © 2014 Elsevier Inc. All rights reserved.
    Clinics in Chest Medicine 12/2014; 35(4). DOI:10.1016/j.ccm.2014.08.015
  • [Show abstract] [Hide abstract]
    ABSTRACT: Our ability to define appropriate molecular targets for preclinical development and develop better methods needs to be improved, to determine the clinical value of novel acute respiratory distress syndrome (ARDS) agents. Clinical trials must have realistic sample sizes and meaningful end points and use the available observation and meta-analytical data to inform design. Biomarker-driven studies or defined ARDS subsets should be considered to categorize specific at-risk populations most likely to benefit from a new treatment. Innovations in clinical trial design should be pursued to improve the outlook for future interventional trials in ARDS. Copyright © 2014 Elsevier Inc. All rights reserved.
    Clinics in Chest Medicine 12/2014; 35(4). DOI:10.1016/j.ccm.2014.08.009